215 related articles for article (PubMed ID: 29720398)
1. Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier.
Bitra A; Doukov T; Croft M; Zajonc DM
J Biol Chem; 2018 Jun; 293(26):9958-9969. PubMed ID: 29720398
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.
Bitra A; Doukov T; Wang J; Picarda G; Benedict CA; Croft M; Zajonc DM
J Biol Chem; 2018 Jan; 293(4):1317-1329. PubMed ID: 29242193
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding.
Bitra A; Doukov T; Destito G; Croft M; Zajonc DM
J Biol Chem; 2019 Feb; 294(6):1831-1845. PubMed ID: 30545939
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of the human 4-1BB/4-1BBL complex.
Gilbreth RN; Oganesyan VY; Amdouni H; Novarra S; Grinberg L; Barnes A; Baca M
J Biol Chem; 2018 Jun; 293(25):9880-9891. PubMed ID: 29720399
[TBL] [Abstract][Full Text] [Related]
5. The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily.
Won EY; Cha K; Byun JS; Kim DU; Shin S; Ahn B; Kim YH; Rice AJ; Walz T; Kwon BS; Cho HS
J Biol Chem; 2010 Mar; 285(12):9202-10. PubMed ID: 20032458
[TBL] [Abstract][Full Text] [Related]
6. Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab.
Chin SM; Kimberlin CR; Roe-Zurz Z; Zhang P; Xu A; Liao-Chan S; Sen D; Nager AR; Oakdale NS; Brown C; Wang F; Yang Y; Lindquist K; Yeung YA; Salek-Ardakani S; Chaparro-Riggers J
Nat Commun; 2018 Nov; 9(1):4679. PubMed ID: 30410017
[TBL] [Abstract][Full Text] [Related]
7. Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab.
Li Y; Tan S; Zhang C; Chai Y; He M; Zhang CW; Wang Q; Tong Z; Liu K; Lei Y; Liu WJ; Liu Y; Tian Z; Cao X; Yan J; Qi J; Tien P; Gao S; Gao GF
Cell Rep; 2018 Oct; 25(4):909-920.e4. PubMed ID: 30355497
[TBL] [Abstract][Full Text] [Related]
8. Analysis of 4-1BBL and laminin binding to murine 4-1BB, a member of the tumor necrosis factor receptor superfamily, and comparison with human 4-1BB.
Loo DT; Chalupny NJ; Bajorath J; Shuford WW; Mittler RS; Aruffo A
J Biol Chem; 1997 Mar; 272(10):6448-56. PubMed ID: 9045669
[TBL] [Abstract][Full Text] [Related]
9. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity.
Rabu C; Quéméner A; Jacques Y; Echasserieau K; Vusio P; Lang F
J Biol Chem; 2005 Dec; 280(50):41472-81. PubMed ID: 16204238
[TBL] [Abstract][Full Text] [Related]
10. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
Zhao Y; Croft M
Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
[TBL] [Abstract][Full Text] [Related]
11. Expression of 4-1BB and 4-1BBL in thymocytes during thymus regeneration.
Kim YM; Kim HK; Kim HJ; Lee HW; Ju SA; Choi BK; Kwon BS; Kim BS; Kim JB; Lim YT; Yoon S
Exp Mol Med; 2009 Dec; 41(12):896-911. PubMed ID: 19745604
[TBL] [Abstract][Full Text] [Related]
12. Constitutive interaction between 4-1BB and 4-1BBL on murine LPS-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS-1 but not 19H3 antibody.
Mbanwi AN; Lin GHY; Wang KC; Watts TH
J Immunol Methods; 2017 Nov; 450():81-89. PubMed ID: 28789924
[TBL] [Abstract][Full Text] [Related]
13. Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB.
Nielsen MA; Juul-Madsen K; Stegmayr J; Gao C; Mehta AY; Greisen SR; Kragstrup TW; Hvid M; Vorup-Jensen T; Cummings RD; Leffler H; Deleuran BW
Front Immunol; 2022; 13():915890. PubMed ID: 35812455
[TBL] [Abstract][Full Text] [Related]
14. Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
Battin C; De Sousa Linhares A; Leitner J; Grossmann A; Lupinek D; Izadi S; Castilho A; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Stritzker J; Steinberger P
Cancer Immunol Immunother; 2023 Sep; 72(9):3029-3043. PubMed ID: 37310433
[TBL] [Abstract][Full Text] [Related]
15. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.
Saoulli K; Lee SY; Cannons JL; Yeh WC; Santana A; Goldstein MD; Bangia N; DeBenedette MA; Mak TW; Choi Y; Watts TH
J Exp Med; 1998 Jun; 187(11):1849-62. PubMed ID: 9607925
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
Wen T; Bukczynski J; Watts TH
J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the 4-1BB/4-1BBL pathway in control of monocyte numbers by invariant NKT cells.
Cole SL; Benam KH; McMichael AJ; Ho LP
J Immunol; 2014 Apr; 192(8):3898-907. PubMed ID: 24639347
[TBL] [Abstract][Full Text] [Related]
18. Deficiency for costimulatory receptor 4-1BB protects against obesity-induced inflammation and metabolic disorders.
Kim CS; Kim JG; Lee BJ; Choi MS; Choi HS; Kawada T; Lee KU; Yu R
Diabetes; 2011 Dec; 60(12):3159-68. PubMed ID: 21998397
[TBL] [Abstract][Full Text] [Related]
19. Activation of c-jun N-terminal kinase by 4-1BB (CD137), a T cell co-stimulatory molecule.
Kim HH; Kwack K; Lee ZH
Mol Cells; 2000 Jun; 10(3):247-52. PubMed ID: 10901161
[TBL] [Abstract][Full Text] [Related]
20. Soluble CD137 (4-1BB) ligand is released following leukocyte activation and is found in sera of patients with hematological malignancies.
Salih HR; Schmetzer HM; Burke C; Starling GC; Dunn R; Pelka-Fleischer R; Nuessler V; Kiener PA
J Immunol; 2001 Oct; 167(7):4059-66. PubMed ID: 11564827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
